Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

S9901 Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Men With Stage III or Stage IV Hodgkin's Disease

Phase 3

Terminated

Conditions: Lymphoma

Interventions: Biological: bleomycin sulfate
Drug: dacarbazine
Drug: carmustine
Drug: doxorubicin hydrochloride
Drug: cyclophosphamide
Drug: vinblastine
Drug: etoposide
Procedure: peripheral blood stem cell transplantation

First Posted Date: 2003-08-28

Last Posted Date: 2013-01-24

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 11

Registration Number: NCT00005090

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸
University of Massachusetts Memorial Medical Center, Worcester, Massachusetts, United States

and more 44 locations

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III Ovarian Cancer

Phase 2

Terminated

Conditions: Malignant Ovarian Mixed Epithelial Tumor
Ovarian Clear Cell Cystadenocarcinoma
Ovarian Endometrioid Adenocarcinoma
Ovarian Mucinous Cystadenocarcinoma
Ovarian Serous Cystadenocarcinoma
Primary Peritoneal Carcinoma
Stage III Ovarian Cancer
Undifferentiated Ovarian Carcinoma

Interventions: Drug: Carboplatin
Drug: Cyclophosphamide
Biological: Filgrastim
Drug: Paclitaxel
Procedure: Peripheral Blood Stem Cell Transplantation
Drug: Topotecan Hydrochloride

First Posted Date: 2003-08-25

Last Posted Date: 2017-08-09

Lead Sponsor: Gynecologic Oncology Group

Target Recruit Count: 12

Registration Number: NCT00004221

Locations: 🇺🇸
Gynecologic Oncology Group, Philadelphia, Pennsylvania, United States

Combination Chemotherapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Has Spread to the Lymph Nodes

Phase 3

Completed

Conditions: Breast Cancer

First Posted Date: 2003-08-25

Last Posted Date: 2023-06-15

Lead Sponsor: Eastern Cooperative Oncology Group

Registration Number: NCT00004125

Locations: 🇺🇸
State University of New York - Upstate Medical University, Syracuse, New York, United States
🇺🇸
CCOP - Syracuse Hematology-Oncology Associates of Central New York, P.C., Syracuse, New York, United States
🇺🇸
CCOP - Southern Nevada Cancer Research Foundation, Las Vegas, Nevada, United States

and more 45 locations

Combination Chemotherapy in Treating Patients With AIDS-Related Hodgkin's Disease

Phase 2

Completed

Conditions: Lymphoma

First Posted Date: 2003-08-13

Last Posted Date: 2010-06-11

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 5

Registration Number: NCT00003114

Locations: 🇺🇸
Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

SWOG-9321 Melphalan, TBI, and Transplant vs Combo Chemo in Untreated Myeloma

Phase 3

Completed

Conditions: Multiple Myeloma

Interventions: Biological: recombinant interferon alfa
Drug: doxorubicin hydrochloride
Drug: carmustine
Drug: melphalan
Drug: cyclophosphamide
Drug: prednisone
Drug: dexamethasone
Drug: vincristine sulfate
Procedure: peripheral blood stem cell transplantation
Procedure: allogeneic bone marrow transplantation
Procedure: autologous bone marrow transplantation
Radiation: radiation therapy

First Posted Date: 2003-08-11

Last Posted Date: 2015-03-06

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 899

Registration Number: NCT00002548

Locations: 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
🇺🇸
New England Medical Center Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

and more 31 locations

Randomized Double Cord Blood Transplant Study

Phase 2

Completed

Conditions: Leukemia, Lymphocytic, Acute
Leukemia, Myelocytic, Acute
Leukemia, Myeloid, Chronic
Lymphoma, Non-Hodgkin

Interventions: Procedure: Expanded allogeneic cord blood (CB)
Procedure: One Unmanipulated and One Expanded Cord Blood Unit
Drug: Rituxan
Drug: Melphalan
Drug: Thiotepa
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Mesna
Radiation: Total body irradiation (TBI)

First Posted Date: 2003-08-11

Last Posted Date: 2019-05-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 110

Registration Number: NCT00067002

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Peripheral Stem Cell Transplant in Treating Patients With High-Risk Leukemia

Phase 2

Terminated

Conditions: Chronic Myeloproliferative Disorders
Leukemia
Myelodysplastic/Myeloproliferative Diseases

First Posted Date: 2003-08-07

Last Posted Date: 2013-05-01

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 51

Registration Number: NCT00066417

Locations: 🇺🇸
NIH - Warren Grant Magnuson Clinical Center, Bethesda, Maryland, United States

Cyclophosphamide, Rituximab, and Either Prednisone or Methylprednisolone in Treating Patients With Lymphoproliferative Disease After Solid Organ Transplantation

Phase 2

Completed

Conditions: Lymphoproliferative Disorder

Interventions: Biological: rituximab
Drug: cyclophosphamide
Drug: methylprednisolone
Drug: prednisone

First Posted Date: 2003-08-07

Last Posted Date: 2019-08-06

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 55

Registration Number: NCT00066469

Locations: 🇺🇸
CCOP - Kalamazoo, Kalamazoo, Michigan, United States
🇺🇸
Loma Linda University Cancer Institute at Loma Linda University Medical Center, Loma Linda, California, United States
🇺🇸
Medical City Dallas Hospital, Dallas, Texas, United States

and more 75 locations

Combination Chemotherapy in Treating Children With Newly Diagnosed Malignant Germ Cell Tumors

Not Applicable

Completed

Conditions: Childhood Germ Cell Tumor
Extragonadal Germ Cell Tumor

Interventions: Biological: bleomycin sulfate
Biological: filgrastim
Drug: cisplatin
Drug: cyclophosphamide
Drug: etoposide
Procedure: conventional surgery
Biological: MESNA

First Posted Date: 2003-08-07

Last Posted Date: 2013-10-17

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 19

Registration Number: NCT00066482

Locations: 🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸
Medical City Dallas Hospital, Dallas, Texas, United States
🇺🇸
Children's Memorial Hospital - Chicago, Chicago, Illinois, United States

and more 95 locations

Combination Chemotherapy, Radiation Therapy, and Bone Marrow Transplantation in Treating Patients With Retinoblastoma

Phase 2

Completed

Conditions: Retinoblastoma

First Posted Date: 2003-07-18

Last Posted Date: 2011-10-04

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 4

Registration Number: NCT00004006

Locations: 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy